RxDoctor Payments Data

Nestor Punay, MD

Neurology · Beaumont, TXNPI 1801870522

Payments from drug & device makers

$233,886in general payments, 2019–2025

Across 1,397 payments — averaging $167.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$211K
  • Acadia Pharmaceuticals Inc$2K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Boston Scientific$1K
  • Lundbeck LLC$1K
  • plus $15K from 54 others

What the payments were for

  • Speaking & faculty fees$206,69788%
  • Travel & lodging$2,4941%
  • Food & beverage$24,45810%
  • Education$2370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)371$210,624
Acadia Pharmaceuticals Inc123$2,049
Biohaven Pharmaceutical Holding Company Ltd.14$1,677
Teva Pharmaceuticals USA, Inc.81$1,421
Boston Scientific16$1,370
Lundbeck LLC61$1,250
EMD Serono, Inc.54$1,194
Pfizer60$1,074
Neuropace, Inc.5$1,070
Amneal Pharmaceuticals LLC48$827
Sunovion Pharmaceuticals Inc.48$719
Neurocrine Biosciences, Inc.36$713
SK Life Science, Inc.37$690
Mallinckrodt Hospital Products Inc.26$636
Sanofi32$620
UCB, Inc.23$610
Abbott14$561
Lilly USA, LLC28$542
Supernus Pharmaceuticals, Inc.37$497
Eisai Inc.27$497
Otsuka America Pharmaceutical, Inc.22$475
Biogen17$345
MDD US Operations, LLC20$331
Argenx US, Inc.11$326
Bristol Myers Squibb13$304
Novartis17$303
Sumitomo Pharma America, Inc.14$269
Biohaven Pharmaceuticals, Inc.12$252
Amgen(2 entities)10$225
Acorda Therapeutics, Inc9$197
CSL Behring11$196
Avion Pharmaceuticals8$157
AstraZeneca(2 entities)7$152
Impel Pharmaceuticals Inc.9$141
Takeda Pharmaceuticals U.S.A., Inc.6$140
Corium, LLC6$128
Kyowa Kirin, Inc.5$118
Grifols USA, LLC5$116
Livanova USA, Inc.2$115
Avanir Pharmaceuticals, Inc.5$96
Johnson & Johnson5$93
GE HealthCare4$87
Arbor Pharmaceuticals, Inc.5$80
Sanofi-aventis U.S. LLC3$62
Aquestive Therapeutics, Inc.4$61
Upsher-smith Laboratories LLC3$54
Akcea Therapeutics, Inc.2$49
Zyla Life Sciences, Inc.2$36
Catalyst Pharmaceuticals, Inc.2$35
Medtronic1$29
Greenwich Biosciences, Inc.2$28
Mallinckrodt Enterprises LLC2$26
Collegium Pharmaceutical, Inc.1$24
Genentech USA, Inc.1$24
ANI Pharmaceuticals, Inc.1$24
Insightec,inc2$23
Assertio Therapeutics, Inc.1$22
Neurelis, Inc.1$20
Merck1$19
Axsome Therapeutics, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$233,886 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$157,225
Medicare patients
271
Services billed
1,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate37$284,895
Gamunex-CImmune Globul G/Gly/Iga Avg 4633$196,891
UbrelvyUbrogepant108$170,547
NuplazidPimavanserin Tartrate30$168,894
RexultiBrexpiprazole80$121,073
QuliptaAtogepant88$114,413
AustedoDeutetrabenazine13$107,981
XcopriCenobamate44$59,718
AptiomEslicarbazepine Acetate30$45,079
NuedextaDextromethorphan Hbr/Quinidine28$44,415
Aimovig AutoinjectorErenumab-Aooe27$24,890
Memantine Hcl1,031$22,981
Nurtec OdtRimegepant Sulfate11$22,678
RytaryCarbidopa/Levodopa11$22,335
OngentysOpicapone12$18,141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$713$303,03649 claims
AbbVieUbrelvy, Qulipta, Botox$210,624$298,523207 claims
Grifols USA, LLCGamunex-C$116$196,89133 claims
Acadia Pharmaceuticals IncNuplazid$2,049$168,89430 claims
Otsuka America Pharmaceutical, Inc.Rexulti$475$121,07380 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,421$107,98113 claims
SK Life Science, Inc.Xcopri$690$59,71844 claims
Sunovion Pharmaceuticals Inc.Aptiom$719$45,07930 claims
Avanir Pharmaceuticals, Inc.Nuedexta$96$44,41528 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$827$24,06932 claims
PfizerNurtec Odt$1,074$22,67811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Beaumont

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →